Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 96(17): 9671-6, 1999 Aug 17.
Article in English | MEDLINE | ID: mdl-10449752

ABSTRACT

c-fos-induced growth factor/vascular endothelial growth factor D (Figf/Vegf-D) is a secreted factor of the VEGF family that binds to the vessel and lymphatic receptors VEGFR-2 and VEGFR-3. Here we report that Figf/Vegf-D is a potent angiogenic factor in rabbit cornea in vivo in a dose-dependent manner. In vitro Figf/Vegf-D induces tyrosine phosphorylation of VEGFR-2 and VEGFR-3 in primary human umbilical cord vein endothelial cells (HUVECs) and in an immortal cell line derived from Kaposi's sarcoma lesion (KS-IMM). The treatment of HUVECs with Figf/Vegf-D induces dose-dependent cell growth. Figf/VEGF-D also induces HUVEC elongation and branching to form an extensive network of capillary-like cords in three-dimensional matrix. In KS-IMM cells Figf/Vegf-D treatment results in dose-dependent mitogenic and motogenic activities. Taken together with the previous observations that Figf/Vegf-D expression is under the control of the nuclear oncogene c-fos, our data uncover a link between a nuclear oncogene and angiogenesis, suggesting that Figf/Vegf-D may play a critical role in tumor cell growth and invasion.


Subject(s)
Endothelial Growth Factors/pharmacology , Neovascularization, Physiologic/drug effects , Proto-Oncogene Proteins c-fos/pharmacology , Animals , CHO Cells , Cell Division/drug effects , Cell Line , Chemotaxis/drug effects , Cornea/blood supply , Cricetinae , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Humans , Mice , Phosphorylation , Rabbits , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cell Surface/metabolism , Receptors, Growth Factor/metabolism , Receptors, Vascular Endothelial Growth Factor , Tyrosine/metabolism , Vascular Endothelial Growth Factor D , Vascular Endothelial Growth Factor Receptor-3
2.
J Biol Chem ; 273(50): 33708-13, 1998 Dec 11.
Article in English | MEDLINE | ID: mdl-9837957

ABSTRACT

The dystrophin gene transcription is up-regulated during muscle cell differentiation. Its expression in muscle cells is induced by the binding of the positive regulators serum response factor and dystrophin promoter bending factor (DPBF) on a regulatory CArG element present on the promoter. Here we show that the dystrophin CArG box is also recognized by the zinc finger nuclear factor YY1. Transient transfection experiments show that YY1 negatively regulates dystrophin transcription in C2C12 muscle cells. On the dystrophin CArG element YY1 competes with the structural factor DPBF. We further show that YY1 and DPBF binding to the CArG element induce opposite DNA bends suggesting that their binding induces alternative promoter structures. Along with C2C12 myotube formation YY1 is reduced and we observed that YY1, but not DPBF, is a substrate of m-calpain, a protease that is up-regulated in muscle cell differentiation. Thus, high levels of YY1 in non-differentiated muscle cells down-regulate the dystrophin promoter, at least in part, by interfering with the spatial organization of the promoter.


Subject(s)
DNA-Binding Proteins/metabolism , Dystrophin/genetics , Gene Expression Regulation , Muscles/metabolism , Promoter Regions, Genetic , Transcription Factors/metabolism , Base Sequence , Calpain/metabolism , Cell Line , DNA Primers , Dystrophin/metabolism , Erythroid-Specific DNA-Binding Factors , Hydrolysis , Muscles/cytology , Protein Binding , Transcription, Genetic , YY1 Transcription Factor
3.
Mol Cell Biol ; 17(3): 1731-43, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9032300

ABSTRACT

The minimal muscle-specific dystrophin promoter contains the consensus sequence CC(A/T)6GG, or the CArG element, which can be found in serum-inducible or muscle-specific promoters. The serum response factor (SRF), which mediates the transcriptional activation of the c-fos gene in response to serum stimulation, can bind to different CArG box elements, suggesting that it could be involved in muscle-constitutive transcription. Here we show that SRF binds to the dystrophin promoter and regulates its muscle-specific transcription. In transient transfections, an altered-binding-specificity SRF mutant restores the muscle-constitutive transcription of a dystrophin promoter with a mutation in its CArG box element. The muscle-constitutive transcription of the dystrophin promoter also requires the sequence GAAACC immediately downstream of the CArG box. This sequence is recognized by a novel DNA bending factor which was named dystrophin promoter-bending factor (DPBF). Mutations of the CArG flanking sequence abolish both DPBF binding and the promoter activity in muscle cells. Its replacement with a p62/ternary complex factor binding site changes the promoter specificity from muscle constitutive to serum responsive. These results show that, on the dystrophin promoter, the transcriptional activation induced by SRF requires the DNA bending induced by DPBF. The bending, next to the CArG box, could promote interactions between SRF and other proteins in the transcriptional complex.


Subject(s)
DNA-Binding Proteins/metabolism , DNA/chemistry , Dystrophin/genetics , Nuclear Proteins/metabolism , Nucleic Acid Conformation , Promoter Regions, Genetic/genetics , 3T3 Cells , Animals , Base Sequence , Cell Extracts , Cell Line , Consensus Sequence , DNA/metabolism , Gene Expression Regulation , Genes, fos/genetics , Humans , Mice , Molecular Sequence Data , Muscles/cytology , Muscles/physiology , Serum Response Factor , Transcription, Genetic , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...